Claims for Patent: 12,134,621

Summary for Patent: 12,134,621

Title:	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Abstract:	The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Inventor(s):	Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Patrick J. Marroum, Peter T. Mayer, Ben Klünder
Assignee:	AbbVie Inc
Application Number:	US18/328,350
Patent Claims:	1. An extended release pharmaceutical tablet comprising: (a) 30 mg of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1); (b) an acidic pH modifier that is an organic acid present in an amount from about 10 w/w% to about 35 w/w%; (c) a release control polymer; and (d) at least one filler. 2. The tablet of claim 1, wherein the extended release pharmaceutical tablet provides for the release of Compound 1 upon entry into a use environment at a rate substantially independent of the pH of the use environment, wherein the use environment has a pH range from about 1.2 to about 6.8. 3. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of microcrystalline cellulose, mannitol, lactose, sucrose and sorbitol. 4. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of microcrystalline cellulose, mannitol, and sorbitol. 5. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of lactose and sucrose. 6. The extended release pharmaceutical tablet of claim 2, wherein the tablet further comprises at least one lubricant selected from the group consisting of polyethylene glycol, magnesium stearate, calcium stearate, sodium stearate, sodium stearyl fumarate and talc. 7. The extended release pharmaceutical tablet of claim 2, wherein the tablet further comprises at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate and sodium stearate. 8. The extended release pharmaceutical tablet of claim 2, wherein the tablet further comprises at least one lubricant selected from the group consisting of calcium stearate and sodium stearate. 9. The extended release pharmaceutical tablet of claim 2, wherein the tablet further comprises at least one glidant selected from the group consisting of colloidal silicon dioxide, calcium silicate, magnesium silicate, and talc. 10. The extended release pharmaceutical tablet of claim 2, wherein the tablet further comprises at least one glidant selected from the group consisting of colloidal silicon dioxide and calcium silicate. 11. The extended release pharmaceutical tablet of claim 2, wherein the tablet further comprises at least one glidant selected from the group consisting of colloidal silicon dioxide. 12. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of microcrystalline cellulose, mannitol, lactose, sucrose and sorbitol; and the tablet further comprises at least one lubricant selected from the group consisting of polyethylene glycol, magnesium stearate, calcium stearate, sodium stearate, sodium stearyl fumarate and talc. 13. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of microcrystalline cellulose and sorbitol; and the tablet further comprises at least one lubricant selected from the group consisting of magnesium stearate. 14. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of microcrystalline cellulose, mannitol, lactose, sucrose and sorbitol; and the tablet further comprises at least one glidant selected from the group consisting of colloidal silicon dioxide, calcium silicate, magnesium silicate, and talc. 15. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of microcrystalline cellulose, mannitol, and sorbitol; and the tablet further comprises at least one glidant which is colloidal silicon dioxide. 16. The extended release pharmaceutical tablet of claim 2, wherein the tablet further comprises: at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate and sodium stearate; and at least one glidant selected from the group consisting of colloidal silicon dioxide and calcium silicate. 17. The extended release pharmaceutical tablet of claim 2, wherein the tablet further comprises: at least one lubricant which is magnesium stearate; and at least one glidant which is colloidal silicon dioxide. 18. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of microcrystalline cellulose, mannitol, lactose, sucrose and sorbitol; and the tablet further comprises: at least one lubricant selected from the group consisting of magnesium stearate, calcium stearate and sodium stearate; and at least one glidant selected from the group consisting of colloidal silicon dioxide, calcium silicate, magnesium silicate, and talc. 19. The extended release pharmaceutical tablet of claim 2, wherein the at least one filler is selected from the group consisting of microcrystalline cellulose, mannitol, and sorbitol; and the tablet further comprises: at least one lubricant which is magnesium stearate; and at least one glidant which is colloidal silicon dioxide. 20. The extended release pharmaceutical tablet of claim 1, wherein the release control polymer is hydroxypropyl methylcellulose. 21. The extended release pharmaceutical tablet of claim 2, wherein the release control polymer is hydroxypropyl methylcellulose. 22. The extended release pharmaceutical tablet of claim 1, wherein the acidic pH modifier is tartaric acid. 23. The extended release pharmaceutical tablet of claim 2, wherein the acidic pH modifier is tartaric acid. 24. The extended release tablet of claim 1, wherein the release control polymer is selected from the group consisting of a cellulose derivative, copolymers of acrylic acid crosslinked with a polyalkenyl polyether, non-ionic homopolymers of ethylene oxide, water-soluble natural gums of polysaccharides, starch, polyvinyl acetate and polyvinylpyrrolidone. 25. The extended release tablet of claim 2, wherein the release control polymer is selected from the group consisting of a cellulose derivative, copolymers of acrylic acid crosslinked with a polyalkenyl polyether, non-ionic homopolymers of ethylene oxide, water-soluble natural gums of polysaccharides, starch, polyvinyl acetate and polyvinylpyrrolidone. 26. The tablet of claim 1, wherein the extended release pharmaceutical tablet, when added to a test medium comprising 900 mL of 50 mM pH 6.8 sodium phosphate buffer at 37° C ± 0.5° C in a standard USP rotating paddle apparatus when the paddles are rotated at 75 rpm ± 4%, releases: (i) not more than about 60% of Compound 1 after passage of about 4 hours; (ii) from about 50% to about 80% of Compound 1 after passage of about 8 hours; (iii) from about 55% to about 90% of Compound 1 after passage of about 10 hours; and (iv) from about 70% to about 100% of Compound 1 after passage of about 20 hours. 27. The tablet of claim 2, wherein the extended release pharmaceutical tablet, when added to a test medium comprising 900 mL of 50 mM pH 6.8 sodium phosphate buffer at 37° C ± 0.5° C in a standard USP rotating paddle apparatus when the paddles are rotated at 75 rpm ± 4%, releases: (i) not more than about 60% of Compound 1 after passage of about 4 hours; (ii) from about 50% to about 80% of Compound 1 after passage of about 8 hours; (iii) from about 55% to about 90% of Compound 1 after passage of about 10 hours; and (iv) from about 70% to about 100% of Compound 1 after passage of about 20 hours. 28. The extended release pharmaceutical tablet of claim 1, wherein: the at least one filler is selected from the group consisting of microcrystalline cellulose, mannitol, lactose, sucrose and sorbitol; and the release control polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, copolymers of acrylic acid, crosslinked with a polyalkenyl polyether, non-ionic homopolymers of ethylene oxide, water soluble natural gums of polysaccharides, starch, polyvinyl acetate and polyvinylpyrrolidone. 29. The extended release pharmaceutical tablet of claim 28, wherein the tablet further comprises at least one lubricant selected from the group consisting of polyethylene glycol, magnesium stearate, calcium stearate, sodium stearate, sodium stearyl fumarate and talc. 30. The extended release pharmaceutical tablet of claim 29, wherein the acidic pH modifier is selected from the group consisting of citric acid, succinic acid, malic acid, fumaric acid and tartaric acid. 31. The extended release pharmaceutical tablet of claim 30, wherein the tablet further comprises at least one glidant selected from the group consisting of colloidal silicon dioxide, calcium silicate, magnesium silicate, and talc. 32. The tablet of claim 31, wherein the extended release pharmaceutical tablet provides for the release of Compound 1 upon entry into a use environment at a rate substantially independent of the pH of the use environment, wherein the use environment has a pH range from about 1.2 to about 6.8.